SARTORIUS AG-VORZUG (SRT3.DE) Fundamental Analysis & Valuation

FRA:SRT3 • DE0007165631

Current stock price

216.6 EUR
+2.2 (+1.03%)
Last:

This SRT3.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. SRT3.DE Profitability Analysis

1.1 Basic Checks

  • SRT3 had positive earnings in the past year.
  • SRT3 had a positive operating cash flow in the past year.
  • SRT3 had positive earnings in each of the past 5 years.
  • Each year in the past 5 years SRT3 had a positive operating cash flow.
SRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFSRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.60%, SRT3 is doing worse than 77.78% of the companies in the same industry.
  • SRT3 has a worse Return On Equity (5.73%) than 72.22% of its industry peers.
  • With a Return On Invested Capital value of 4.97%, SRT3 is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
  • The Average Return On Invested Capital over the past 3 years for SRT3 is below the industry average of 9.03%.
  • The 3 year average ROIC (4.49%) for SRT3 is below the current ROIC(4.97%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.6%
ROE 5.73%
ROIC 4.97%
ROA(3y)1.51%
ROA(5y)3.97%
ROE(3y)6.23%
ROE(5y)15.62%
ROIC(3y)4.49%
ROIC(5y)9.01%
SRT3.DE Yearly ROA, ROE, ROICSRT3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 4.38%, SRT3 is doing worse than 72.22% of the companies in the same industry.
  • SRT3's Profit Margin has declined in the last couple of years.
  • SRT3's Operating Margin of 15.34% is in line compared to the rest of the industry. SRT3 outperforms 50.00% of its industry peers.
  • In the last couple of years the Operating Margin of SRT3 has declined.
  • SRT3 has a better Gross Margin (46.26%) than 66.67% of its industry peers.
  • SRT3's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 15.34%
PM (TTM) 4.38%
GM 46.26%
OM growth 3Y-16.16%
OM growth 5Y-5.98%
PM growth 3Y-35.4%
PM growth 5Y-13.41%
GM growth 3Y-3.93%
GM growth 5Y-2.18%
SRT3.DE Yearly Profit, Operating, Gross MarginsSRT3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1

2. SRT3.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SRT3 is destroying value.
  • SRT3 has about the same amout of shares outstanding than it did 1 year ago.
  • SRT3 has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, SRT3 has an improved debt to assets ratio.
SRT3.DE Yearly Shares OutstandingSRT3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
SRT3.DE Yearly Total Debt VS Total AssetsSRT3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • SRT3 has an Altman-Z score of 2.27. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of SRT3 (2.27) is worse than 61.11% of its industry peers.
  • SRT3 has a debt to FCF ratio of 10.84. This is a negative value and a sign of low solvency as SRT3 would need 10.84 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 10.84, SRT3 is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
  • SRT3 has a Debt/Equity ratio of 1.24. This is a high value indicating a heavy dependency on external financing.
  • SRT3 has a worse Debt to Equity ratio (1.24) than 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF 10.84
Altman-Z 2.27
ROIC/WACC0.64
WACC7.71%
SRT3.DE Yearly LT Debt VS Equity VS FCFSRT3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.3 Liquidity

  • SRT3 has a Current Ratio of 0.90. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SRT3's Current ratio of 0.90 is on the low side compared to the rest of the industry. SRT3 is outperformed by 83.33% of its industry peers.
  • SRT3 has a Quick Ratio of 0.90. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of SRT3 (0.50) is worse than 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.5
SRT3.DE Yearly Current Assets VS Current LiabilitesSRT3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

6

3. SRT3.DE Growth Analysis

3.1 Past

  • SRT3 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.46%, which is quite impressive.
  • Measured over the past 5 years, SRT3 shows a small growth in Earnings Per Share. The EPS has been growing by 1.76% on average per year.
  • The Revenue has been growing slightly by 4.66% in the past year.
  • The Revenue has been growing by 8.66% on average over the past years. This is quite good.
EPS 1Y (TTM)83.46%
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
Revenue 1Y (TTM)4.66%
Revenue growth 3Y-5.37%
Revenue growth 5Y8.66%
Sales Q2Q%2.29%

3.2 Future

  • SRT3 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.39% yearly.
  • The Revenue is expected to grow by 8.94% on average over the next years. This is quite good.
EPS Next Y19.16%
EPS Next 2Y18.45%
EPS Next 3Y18.59%
EPS Next 5Y16.39%
Revenue Next Year6.1%
Revenue Next 2Y7.92%
Revenue Next 3Y8.69%
Revenue Next 5Y8.94%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SRT3.DE Yearly Revenue VS EstimatesSRT3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B
SRT3.DE Yearly EPS VS EstimatesSRT3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

1

4. SRT3.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • SRT3 is valuated quite expensively with a Price/Earnings ratio of 45.31.
  • Based on the Price/Earnings ratio, SRT3 is valued more expensive than 83.33% of the companies in the same industry.
  • SRT3's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.18.
  • A Price/Forward Earnings ratio of 38.03 indicates a quite expensive valuation of SRT3.
  • Based on the Price/Forward Earnings ratio, SRT3 is valued a bit more expensive than 77.78% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of SRT3 to the average of the S&P500 Index (37.96), we can say SRT3 is valued inline with the index average.
Industry RankSector Rank
PE 45.31
Fwd PE 38.03
SRT3.DE Price Earnings VS Forward Price EarningsSRT3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • SRT3's Enterprise Value to EBITDA is on the same level as the industry average.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as SRT3.
Industry RankSector Rank
P/FCF 41.05
EV/EBITDA 20.71
SRT3.DE Per share dataSRT3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SRT3 does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as SRT3's earnings are expected to grow with 18.59% in the coming years.
PEG (NY)2.36
PEG (5Y)25.7
EPS Next 2Y18.45%
EPS Next 3Y18.59%

4

5. SRT3.DE Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.44%, SRT3 is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.52, SRT3 pays a bit more dividend than its industry peers.
  • With a Dividend Yield of 0.44, SRT3 pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.44%

5.2 History

  • The dividend of SRT3 is nicely growing with an annual growth rate of 15.65%!
Dividend Growth(5Y)15.65%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 32.71% of the earnings are spent on dividend by SRT3. This is a low number and sustainable payout ratio.
  • SRT3's earnings are growing around the same pace than its dividend. As long as the earnings growth is kept the dividend growth is sustainable.
DP32.71%
EPS Next 2Y18.45%
EPS Next 3Y18.59%
SRT3.DE Yearly Income VS Free CF VS DividendSRT3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
SRT3.DE Dividend Payout.SRT3.DE Dividend Payout, showing the Payout Ratio.SRT3.DE Dividend Payout.PayoutRetained Earnings

SRT3.DE Fundamentals: All Metrics, Ratios and Statistics

SARTORIUS AG-VORZUG

FRA:SRT3 (4/13/2026, 5:36:15 PM)

216.6

+2.2 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)04-23
Inst Owners1.97%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.22B
Revenue(TTM)3.54B
Net Income(TTM)155.00M
Analysts80
Price Target376.38 (73.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.44%
Yearly Dividend0.73
Dividend Growth(5Y)15.65%
DP32.71%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.19%
Min EPS beat(2)4.83%
Max EPS beat(2)7.55%
EPS beat(4)2
Avg EPS beat(4)-0.57%
Min EPS beat(4)-10.52%
Max EPS beat(4)7.55%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.53%
Min Revenue beat(2)0.24%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)2.67%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.02%
PT rev (3m)8.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.19%
EPS NY rev (3m)-5.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.7%
Revenue NY rev (3m)-1.83%
Valuation
Industry RankSector Rank
PE 45.31
Fwd PE 38.03
P/S 4.58
P/FCF 41.05
P/OCF 19.38
P/B 5.99
P/tB N/A
EV/EBITDA 20.71
EPS(TTM)4.78
EY2.21%
EPS(NY)5.7
Fwd EY2.63%
FCF(TTM)5.28
FCFY2.44%
OCF(TTM)11.18
OCFY5.16%
SpS47.25
BVpS36.15
TBVpS-34.61
PEG (NY)2.36
PEG (5Y)25.7
Graham Number62.35
Profitability
Industry RankSector Rank
ROA 1.6%
ROE 5.73%
ROCE 7%
ROIC 4.97%
ROICexc 5.35%
ROICexgc 20.27%
OM 15.34%
PM (TTM) 4.38%
GM 46.26%
FCFM 11.17%
ROA(3y)1.51%
ROA(5y)3.97%
ROE(3y)6.23%
ROE(5y)15.62%
ROIC(3y)4.49%
ROIC(5y)9.01%
ROICexc(3y)4.83%
ROICexc(5y)9.64%
ROICexgc(3y)16.7%
ROICexgc(5y)28.15%
ROCE(3y)6.33%
ROCE(5y)12.7%
ROICexgc growth 3Y-19.62%
ROICexgc growth 5Y-7.23%
ROICexc growth 3Y-29.84%
ROICexc growth 5Y-12.08%
OM growth 3Y-16.16%
OM growth 5Y-5.98%
PM growth 3Y-35.4%
PM growth 5Y-13.41%
GM growth 3Y-3.93%
GM growth 5Y-2.18%
F-Score7
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF 10.84
Debt/EBITDA 3.49
Cap/Depr 105.19%
Cap/Sales 12.49%
Interest Coverage 3
Cash Conversion 86.94%
Profit Quality 254.9%
Current Ratio 0.9
Quick Ratio 0.5
Altman-Z 2.27
F-Score7
WACC7.71%
ROIC/WACC0.64
Cap/Depr(3y)122.42%
Cap/Depr(5y)145.08%
Cap/Sales(3y)13.7%
Cap/Sales(5y)13.08%
Profit Quality(3y)357.39%
Profit Quality(5y)249.46%
High Growth Momentum
Growth
EPS 1Y (TTM)83.46%
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
EPS Next Y19.16%
EPS Next 2Y18.45%
EPS Next 3Y18.59%
EPS Next 5Y16.39%
Revenue 1Y (TTM)4.66%
Revenue growth 3Y-5.37%
Revenue growth 5Y8.66%
Sales Q2Q%2.29%
Revenue Next Year6.1%
Revenue Next 2Y7.92%
Revenue Next 3Y8.69%
Revenue Next 5Y8.94%
EBIT growth 1Y38.38%
EBIT growth 3Y-20.66%
EBIT growth 5Y2.17%
EBIT Next Year81.03%
EBIT Next 3Y32.63%
EBIT Next 5Y24.23%
FCF growth 1Y-30.23%
FCF growth 3Y23.14%
FCF growth 5Y7.81%
OCF growth 1Y-14.26%
OCF growth 3Y4.46%
OCF growth 5Y10.35%

SARTORIUS AG-VORZUG / SRT3.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRT3.DE.


Can you provide the valuation status for SARTORIUS AG-VORZUG?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.


What is the profitability of SRT3 stock?

SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for SRT3 stock?

The Earnings per Share (EPS) of SARTORIUS AG-VORZUG (SRT3.DE) is expected to grow by 19.16% in the next year.


Can you provide the dividend sustainability for SRT3 stock?

The dividend rating of SARTORIUS AG-VORZUG (SRT3.DE) is 4 / 10 and the dividend payout ratio is 32.71%.